These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1540 related items for PubMed ID: 27761814

  • 1. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM, Roth DM, Marchal C, Bouchecareilh M.
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [Abstract] [Full Text] [Related]

  • 2. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
    Hutt DM, Roth DM, Vignaud H, Cullin C, Bouchecareilh M.
    PLoS One; 2014; 9(8):e106224. PubMed ID: 25166596
    [Abstract] [Full Text] [Related]

  • 3. Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs).
    Mackmull MT, Iskar M, Parca L, Singer S, Bork P, Ori A, Beck M.
    Mol Cell Proteomics; 2015 May; 14(5):1350-60. PubMed ID: 25755299
    [Abstract] [Full Text] [Related]

  • 4. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
    Richon VM, Sandhoff TW, Rifkind RA, Marks PA.
    Proc Natl Acad Sci U S A; 2000 Aug 29; 97(18):10014-9. PubMed ID: 10954755
    [Abstract] [Full Text] [Related]

  • 5. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y, Seto E.
    Cold Spring Harb Perspect Med; 2016 Oct 03; 6(10):. PubMed ID: 27599530
    [Abstract] [Full Text] [Related]

  • 6. Assessment of HDACi-Induced Cytotoxicity.
    Marx-Blümel L, Marx C, Kühne M, Sonnemann J.
    Methods Mol Biol; 2017 Oct 03; 1510():23-45. PubMed ID: 27761811
    [Abstract] [Full Text] [Related]

  • 7. HDAC Inhibitors.
    Olzscha H, Bekheet ME, Sheikh S, La Thangue NB.
    Methods Mol Biol; 2016 Oct 03; 1436():281-303. PubMed ID: 27246222
    [Abstract] [Full Text] [Related]

  • 8. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M, Kiweler N, Mahboobi S, Krämer OH.
    Methods Mol Biol; 2017 Oct 03; 1510():355-364. PubMed ID: 27761834
    [Abstract] [Full Text] [Related]

  • 9. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, Marks PA.
    Mol Cancer Ther; 2007 Sep 03; 6(9):2525-34. PubMed ID: 17876049
    [Abstract] [Full Text] [Related]

  • 10. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
    Fischer C, Leithner K, Wohlkoenig C, Quehenberger F, Bertsch A, Olschewski A, Olschewski H, Hrzenjak A.
    Mol Cancer; 2015 Jan 21; 14():4. PubMed ID: 25608569
    [Abstract] [Full Text] [Related]

  • 11. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
    Vahid F, Zand H, Nosrat-Mirshekarlou E, Najafi R, Hekmatdoost A.
    Gene; 2015 May 10; 562(1):8-15. PubMed ID: 25701602
    [Abstract] [Full Text] [Related]

  • 12. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M, Lassmann S.
    Epigenetics; 2015 May 10; 10(5):431-45. PubMed ID: 25923331
    [Abstract] [Full Text] [Related]

  • 13. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ, Dedes I, Imesch P, von Bueren AO, Fink D, Fedier A.
    Anticancer Drugs; 2009 Jun 10; 20(5):321-33. PubMed ID: 19322073
    [Abstract] [Full Text] [Related]

  • 14. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
    Codd R, Braich N, Liu J, Soe CZ, Pakchung AA.
    Int J Biochem Cell Biol; 2009 Apr 10; 41(4):736-9. PubMed ID: 18725319
    [Abstract] [Full Text] [Related]

  • 15. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM.
    Epigenomics; 2010 Jun 10; 2(3):457-65. PubMed ID: 22121904
    [Abstract] [Full Text] [Related]

  • 16. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
    Méhul B, Perrin A, Grisendi K, Galindo AN, Dayon L, Ménigot C, Rival Y, Voegel JJ.
    J Proteomics; 2018 Sep 15; 187():126-143. PubMed ID: 30012418
    [Abstract] [Full Text] [Related]

  • 17. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
    Liu ZH, Li J, Xia J, Jiang R, Zuo GW, Li XP, Chen Y, Xiong W, Chen DL.
    Chem Biol Interact; 2015 Dec 05; 242():227-34. PubMed ID: 26482938
    [Abstract] [Full Text] [Related]

  • 18. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
    Kim HM, Kim CS, Lee JH, Jang SJ, Hwang JJ, Ro S, Hyun YL, Choi J.
    Breast Cancer Res Treat; 2011 Nov 05; 130(2):365-75. PubMed ID: 21184271
    [Abstract] [Full Text] [Related]

  • 19. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA.
    Urol Oncol; 2013 Nov 05; 31(8):1770-9. PubMed ID: 22944197
    [Abstract] [Full Text] [Related]

  • 20. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.
    J Cancer Res Clin Oncol; 2016 Feb 05; 142(2):379-87. PubMed ID: 26314218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.